Company / SG&A Expense
GRAIL, Inc. SG&A Expense History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$159.1M
FY2025
5-year range
$159.1M / $213.9M
FY2022-FY2025
Trend
-25.6%
vs FY2024
Sector context
#116 of 158
Health Care
What the data says
At $159M, GRAIL, Inc.'s sg&a expense ranks #43 of 158 in the Health Care sector. Improved from $200M to $159M over the past 2 years.
Based on SEC 10-K filings.
$159M in FY2025 with a 3-year CAGR of -3.0%.
Improved from $200M to $159M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -3.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#43 of 158 in Health CareTop 27% of 158This company $159.1M Sector average $175.9B
▼
-99.9% below sector average
Key checks
Key Insights
- 3-year CAGR of -3.0%, indicating a declining trend.
- In FY2025, sg&a expense decreased 25.6% year-over-year.
- Ranks #116 out of 158 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $159.1M | -25.6% |
| FY2024 | $213.9M | +6.8% |
| FY2023 | $200.3M | +15.0% |
| FY2022 | $174.1M | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026